17 Aug Gadolinium-Based Contrast Agents – Deposition in the brain
Posted at 12:59h
in
The following pharmaceutical companies: AXIM Pharmaceuticals (Pty) Ltd, Guerbet South Africa (Pty) Ltd and GE Healthcare SA in collaboration with South African Health Products Regulatory Authority (SAHPRA) would like to inform you of the safety information regarding the risk of gadolinium brain deposition following the use of GBCA's.
2019 Apr
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
11/04/2019
File Type:
pdf
Category:
Communication To Health Care Professionals